CliffBio
small molecule

XURIDEN

URIDINE TRIACETATE

Loss of exclusivity—loss of exclusivity
CompanyBTG INTERNATIONAL INC

Drug detail

Brand nameXURIDEN
Active ingredientURIDINE TRIACETATE
Strength2GM/PACKET
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2015
Marketing statusRX

More from BTG INTERNATIONAL INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.